Savara Inc (SVRA) Given Consensus Rating of “Buy” by Analysts
Savara Inc (NASDAQ:SVRA) has been given a consensus rating of “Buy” by the eight analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $26.40.
Several equities research analysts have recently issued reports on SVRA shares. Roth Capital lowered their target price on shares of Savara from $40.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, October 31st. Canaccord Genuity raised their target price on shares of Savara from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 30th. ValuEngine lowered shares of Savara from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. BidaskClub lowered shares of Savara from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 9th. Finally, Zacks Investment Research lowered shares of Savara from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd.
Several institutional investors have recently added to or reduced their stakes in SVRA. Deutsche Bank AG lifted its holdings in Savara by 136,538.5% during the 4th quarter. Deutsche Bank AG now owns 17,763 shares of the company’s stock valued at $263,000 after buying an additional 17,750 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in Savara during the 4th quarter valued at about $353,000. Virtu Financial LLC bought a new stake in Savara during the 4th quarter valued at about $464,000. Renaissance Technologies LLC lifted its holdings in Savara by 260.2% during the 4th quarter. Renaissance Technologies LLC now owns 37,483 shares of the company’s stock valued at $556,000 after buying an additional 27,076 shares in the last quarter. Finally, Brown Advisory Inc. bought a new stake in Savara during the 4th quarter valued at about $2,098,000. Hedge funds and other institutional investors own 18.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Savara Inc (SVRA) Given Consensus Rating of “Buy” by Analysts” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/14/savara-inc-svra-given-consensus-rating-of-buy-by-analysts.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.